title: Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.
abstract: Farnesyltransferase inhibitors (FTIs) represent a new class of signal transduction inhibitors that block the processing of cellular polypeptides that have cysteine terminal residues and, by so doing, interdict multiple pathways involved in proliferation and survival of diverse malignant cell types. Tipifarnib is an orally bioavailable, nonpeptidomimetic methylquinolone FTI that has exhibited clinical activity in patients with myeloid malignancies including elderly adults with acute myelogenous leukemia (AML) who are not candidates for traditional cytotoxic chemotherapy, patients with high-risk myelodysplasia, myeloproliferative disorders, and imatinib-resistant chronic myelogenous leukemia. Because of its relatively low toxicity profile, tipifarnib provides an important alternative to traditional cytotoxic approaches for elderly patients who are not likely to tolerate or even benefit from aggressive chemotherapy. In this review, we will focus on the clinical development of tipifarnib for treatment of newly diagnosed AML, both as induction therapy for elderly adults with poor-risk AML and as maintenance therapy following achievement of first complete remission following induction and consolidation therapies for poor-risk AML. As with all other malignancies, the optimal approach is likely to lie in rational combinations of tipifarnib with cytotoxic, biologic and/or immunomodulatory agents with non-cross-resistant mechanisms of action. Gene expression profiling has identified networks of differentially expressed genes and gene combinations capable of predicting response to single agent tipifarnib. The clinical and correlative laboratory trials in progress and under development will provide the critical foundations for defining the optimal roles of tipifarnib and in patients with AMl and other hematologic malignancies.
authors.affiliation: Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA;
authors.forename: Judith E
authors.initials: JE
authors.lastname: Karp
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Lancet
references.citation: Leukemia. 2009 Apr;23(4):631-4
references.pmid: 19092853
references.citation: Leukemia. 2007 Sep;21(9):1964-70
references.pmid: 17581608
references.citation: Annu Rev Pharmacol Toxicol. 2001;41:53-77
references.pmid: 11264450
references.citation: Clin Cancer Res. 2007 Apr 1;13(7):2254-60
references.pmid: 17404110
references.citation: Blood. 2008 Mar 1;111(5):2589-96
references.pmid: 18160667
references.citation: Blood. 2001 Aug 1;98(3):548-53
references.pmid: 11468148
references.citation: Blood. 2009 Aug 6;114(6):1166-73
references.pmid: 19470696
references.citation: Oncogene. 1999 Dec 9;18(52):7514-26
references.pmid: 10602510
references.citation: Hematol Oncol Clin North Am. 2000 Feb;14(1):251-67
references.pmid: 10680081
references.citation: Trends Biochem Sci. 2003 Nov;28(11):573-6
references.pmid: 14607085
references.citation: Leuk Res. 2003 Apr;27(4):313-21
references.pmid: 12531222
references.citation: J Clin Oncol. 2007 May 10;25(14):1908-15
references.pmid: 17488990
references.citation: Leukemia. 1997 Aug;11(8):1193-6
references.pmid: 9264368
references.citation: Blood. 2007 Feb 15;109(4):1387-94
references.pmid: 17082323
references.citation: Blood. 2001 Sep 1;98(5):1302-11
references.pmid: 11520775
references.citation: Blood. 1999 Aug 1;94(3):1086-99
references.pmid: 10419902
references.citation: Curr Treat Options Oncol. 2006 Jul;7(4):285-94
references.pmid: 16916489
references.citation: Blood. 2006 Sep 1;108(5):1677-83
references.pmid: 16670265
references.citation: Science. 2006 Mar 31;311(5769):1887-93
references.pmid: 16543417
references.citation: Blood. 2007 Sep 15;110(6):2102-9
references.pmid: 17536018
references.citation: Clin Cancer Res. 2002 Jun;8(6):2002-9
references.pmid: 12060646
references.citation: Nat Rev Mol Cell Biol. 2002 Jun;3(6):430-40
references.pmid: 12042765
references.citation: J Clin Oncol. 1999 Dec;17(12):3835-49
references.pmid: 10577857
references.citation: J Clin Oncol. 2004 Apr 1;22(7):1287-92
references.pmid: 15051776
references.citation: Lancet. 1982 Dec 11;2(8311):1345-6
references.pmid: 6128632
references.citation: J Biol Chem. 1995 Apr 21;270(16):9031-4
references.pmid: 7721814
references.citation: Ann Hematol. 2006 Mar;85(3):139-63
references.pmid: 16391911
references.citation: J Clin Oncol. 2005 Mar 20;23(9):1969-78
references.pmid: 15632409
references.citation: Semin Oncol. 2004 Feb;31(1 Suppl 1):28-39
references.pmid: 14981578
references.citation: Blood. 2006 May 1;107(9):3481-5
references.pmid: 16455952
references.citation: Blood. 2001 Sep 1;98(5):1312-20
references.pmid: 11520776
references.citation: Invest New Drugs. 1999;17(3):241-58
references.pmid: 10665477
references.citation: Blood. 2007 Jun 15;109(12):5151-6
references.pmid: 17351110
references.citation: Blood. 1990 Jan 1;75(1):27-32
references.pmid: 2403818
references.citation: Science. 2006 Mar 17;311(5767):1621-3
references.pmid: 16484451
references.citation: J Biol Chem. 1999 Sep 17;274(38):27010-7
references.pmid: 10480914
references.citation: Haematologica. 2003 Feb;88(2):229-30
references.pmid: 12604418
references.citation: J Clin Oncol. 2006 Jun 1;24(16):2480-9
references.pmid: 16735702
references.citation: Proc Natl Acad Sci U S A. 1991 May 1;88(9):3812-6
references.pmid: 2023931
references.citation: Blood. 2001 Jun 1;97(11):3361-9
references.pmid: 11369625
references.citation: Blood. 2005 Aug 15;106(4):1355-61
references.pmid: 15860663
references.citation: Mol Pharmacol. 2005 Aug;68(2):477-86
references.pmid: 15901852
references.citation: Blood. 1992 Apr 15;79(8):1924-30
references.pmid: 1562720
references.citation: Am J Clin Pathol. 2003 May;119(5):672-80
references.pmid: 12760285
references.citation: Blood. 2006 Jul 15;108(2):685-96
references.pmid: 16597596
references.citation: Blood. 2007 May 15;109(10):4158-63
references.pmid: 17264294
references.citation: Clin Cancer Res. 2005 Aug 15;11(16):6057-64
references.pmid: 16115951
references.citation: Nature. 2006 Oct 12;443(7112):713-6
references.pmid: 16964241
references.citation: Blood. 2005 Nov 15;106(10):3532-7
references.pmid: 16051737
references.citation: Mol Cancer Ther. 2004 Feb;3(2):179-86
references.pmid: 14985458
references.citation: Ann Hematol. 2005 Apr;84(4):227-31
references.pmid: 15517268
references.citation: Leukemia. 2007 Apr;21(4):739-46
references.pmid: 17268526
references.citation: Blood. 2003 Dec 15;102(13):4527-34
references.pmid: 12947010
references.citation: Cancer Invest. 2007 Sep;25(6):484-94
references.pmid: 17882662
references.citation: Blood. 2004 Oct 1;104(7):1940-51
references.pmid: 15217827
references.citation: Leukemia. 1999 Jun;13(6):843-9
references.pmid: 10360370
references.citation: Mol Pharmacol. 2005 Jun;67(6):1991-8
references.pmid: 15738311
references.citation: Clin Cancer Res. 2006 Jan 15;12(2):591-9
references.pmid: 16428505
references.citation: Blood. 2007 Jan 15;109(2):431-48
references.pmid: 16960150
references.citation: BMC Cancer. 2004 Aug 25;4:56
references.pmid: 15329151
references.citation: J Clin Oncol. 1998 Mar;16(3):872-81
references.pmid: 9508168
references.citation: Cancer Res. 1996 Jun 1;56(11):2626-32
references.pmid: 8653708
references.citation: Blood. 2000 Sep 1;96(5):1655-69
references.pmid: 10961860
references.citation: J Lipid Res. 2006 Jan;47(1):15-31
references.pmid: 16278491
references.citation: Eur J Haematol. 2004 Dec;73(6):418-26
references.pmid: 15522064
references.citation: J Biol Chem. 2003 Aug 29;278(35):32493-6
references.pmid: 12842888
references.citation: Blood. 2003 Mar 1;101(5):1692-7
references.pmid: 12411300
references.citation: N Engl J Med. 2004 Apr 15;350(16):1605-16
references.pmid: 15084693
references.citation: Oncogene. 1994 Feb;9(2):621-8
references.pmid: 8290273
references.citation: Eur J Haematol. 2005 May;74(5):418-23
references.pmid: 15813916
references.citation: Mol Cell Biol. 2000 Jan;20(1):139-48
references.pmid: 10594016
references.citation: Nat Rev Cancer. 2003 Dec;3(12):945-51
references.pmid: 14737124